Stocks Health care BOLD
NASDAQ · Health careBoundless Bio, Inc. (BOLD)
It posted a net loss of $64M. In fiscal 2025 capital spending exceeded operating cash flow by $47.2M. At June 30, 2026 it held $20.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 7, 2026.
What Boundless Bio, Inc. does
Boundless Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BOLD.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$58.2M | -$2.60 | -$47.2M |
| 2024 | n/a | -$65.4M | -$3.85 | -$63.4M |
| 2024 | n/a | -$49.4M | -$40.65 | -$47.5M |
Latest SEC filings
What Boundless Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 28, 2026Form 425 filing 425
- August 28, 2026
- August 27, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake (5% or more) SCHEDULE 13G
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 7, 2026Quarterly report 10-Q · period to June 30, 2026
- June 29, 2026Passive stake (5% or more) SCHEDULE 13G
- June 23, 2026Form 425 filing 425
- June 23, 2026
- June 17, 2026
Questions about BOLD
What does Boundless Bio, Inc. do?
Boundless Bio, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BOLD.
Is Boundless Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $64M.
When did Boundless Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 7, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the form 425 filing from August 28, 2026.
Similar companies
Follow BOLD
Get an email when Boundless Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow BOLD: get an email when it filesWhere the numbers come from
Financial figures are the values Boundless Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.